Werth Ventures

DeepLook Medical develops advanced medical imaging software aimed at enhancing the detection of early breast cancer in mammograms. Utilizing shape-recognition technology, the software extracts and analyzes data from radiological images, particularly focusing on dense breast tissue where critical details may be obscured. By revealing radiomic features that reflect tissue morphology, the software helps physicians identify subtle indicators of breast cancer that are often undetectable by the human eye. This capability not only improves diagnostic accuracy but also reduces the likelihood of unnecessary surgical interventions by minimizing false positives in mammography results. Additionally, DeepLook Medical offers a phenotype database for breast cancer morphology, which is currently available for research purposes.

Cingulate Therapeutics, LLC is a biopharmaceutical company focused on developing treatments for central nervous system and neurobiological disorders, particularly Attention Deficit and Hyperactivity Disorder (ADHD). Founded in 2012 and based in Kansas City, Kansas, with an additional office in Morristown, New Jersey, the company is advancing two first-line stimulant medications, CTx-1301 and CTx-1302, designed for all patient demographics, including children, adolescents, and adults. These medications aim to address a significant unmet need in the ADHD market by providing full-day therapeutic efficacy through a single daily oral dose. Cingulate has partnered with Catalent Pharma Solutions to leverage their patented OptiDose technology, which enhances drug delivery and manufacturing efficiency. The company holds a robust intellectual property portfolio, including 28 patents, ensuring strong protection throughout the development process. With ongoing research indicating that many patients require additional dosing for optimal results, Cingulate's innovations target the growing $2-$3 billion combination-dose market and the broader $9 billion ADHD market.

Cingulate Therapeutics, LLC is a biopharmaceutical company focused on developing treatments for central nervous system and neurobiological disorders, particularly Attention Deficit and Hyperactivity Disorder (ADHD). Founded in 2012 and based in Kansas City, Kansas, with an additional office in Morristown, New Jersey, the company is advancing two first-line stimulant medications, CTx-1301 and CTx-1302, designed for all patient demographics, including children, adolescents, and adults. These medications aim to address a significant unmet need in the ADHD market by providing full-day therapeutic efficacy through a single daily oral dose. Cingulate has partnered with Catalent Pharma Solutions to leverage their patented OptiDose technology, which enhances drug delivery and manufacturing efficiency. The company holds a robust intellectual property portfolio, including 28 patents, ensuring strong protection throughout the development process. With ongoing research indicating that many patients require additional dosing for optimal results, Cingulate's innovations target the growing $2-$3 billion combination-dose market and the broader $9 billion ADHD market.

Cingulate Therapeutics, LLC is a biopharmaceutical company focused on developing treatments for central nervous system and neurobiological disorders, particularly Attention Deficit and Hyperactivity Disorder (ADHD). Founded in 2012 and based in Kansas City, Kansas, with an additional office in Morristown, New Jersey, the company is advancing two first-line stimulant medications, CTx-1301 and CTx-1302, designed for all patient demographics, including children, adolescents, and adults. These medications aim to address a significant unmet need in the ADHD market by providing full-day therapeutic efficacy through a single daily oral dose. Cingulate has partnered with Catalent Pharma Solutions to leverage their patented OptiDose technology, which enhances drug delivery and manufacturing efficiency. The company holds a robust intellectual property portfolio, including 28 patents, ensuring strong protection throughout the development process. With ongoing research indicating that many patients require additional dosing for optimal results, Cingulate's innovations target the growing $2-$3 billion combination-dose market and the broader $9 billion ADHD market.

Torigen Pharmaceuticals is dedicated to advancing cancer care for companion animals through innovative treatment options. Founded in 2013 and based in Farmington, Connecticut, the company focuses on developing immunotherapy solutions, particularly an experimental autologous cancer vaccine. This vaccine aims to activate the immune system to target specific tumor-associated antigens present on cancer cells, allowing for more effective detection and treatment of tumors. By providing alternatives to traditional, invasive methods such as surgeries and chemotherapy, Torigen seeks to improve the quality of life for pets facing cancer. The company builds on years of scientific research and is committed to pushing the boundaries of veterinary oncology.

QRfertile LLC, based in Farmington, Connecticut, develops and manufactures a male fertility test kit that enables customers to perform tests at home. Founded in 2018, the company provides a comprehensive platform that not only allows men to assess their fertility but also connects them with physicians for guidance on improving reproductive health. QRfertile's offerings aim to make male health care more accessible and affordable, addressing a significant need in the market. By integrating modern technology with health consultations, the company enhances patient engagement and facilitates better health outcomes for men, ultimately aiming to improve their overall lifestyle and well-being.

VeraDermics is a dermatology company focused on developing innovative solutions for skin conditions, particularly warts. The company has created a dissolvable microneedle patch that delivers immunotherapy painlessly, stimulating the body's immune response to combat the wart virus. This patch is designed to be applied like a bandage and remains on the skin for less than an hour. During this time, the microneedles, made from immune stimulators embedded in a polymer matrix, dissolve and are implanted into the skin. After the adhesive backing is removed, the microneedles continue to dissolve over the following weeks, releasing immune stimulators directly into the wart. This method not only provides a pain-free treatment option but also simplifies the administration process for medical practitioners and enhances patient comfort.

MedRhythms Inc. is a neuro-rehabilitation company that specializes in neurologic music therapy, employing sensors, music, and artificial intelligence to create evidence-based interventions. Founded in 2013 and based in Boston, Massachusetts, MedRhythms aims to assist individuals affected by conditions such as traumatic brain injury, stroke, Parkinson's disease, and Huntington's disease. The company's approach focuses on the intersection of music, neuroscience, and technology, developing programs to enhance sensorimotor, speech, language, and cognitive functions. By utilizing innovative methodologies, MedRhythms enables patients to leverage music as a therapeutic tool to stimulate brain activity and improve their walking and functional outcomes.

QRfertile LLC, based in Farmington, Connecticut, develops and manufactures a male fertility test kit that enables customers to perform tests at home. Founded in 2018, the company provides a comprehensive platform that not only allows men to assess their fertility but also connects them with physicians for guidance on improving reproductive health. QRfertile's offerings aim to make male health care more accessible and affordable, addressing a significant need in the market. By integrating modern technology with health consultations, the company enhances patient engagement and facilitates better health outcomes for men, ultimately aiming to improve their overall lifestyle and well-being.

Cingulate Therapeutics, LLC is a biopharmaceutical company focused on developing treatments for central nervous system and neurobiological disorders, particularly Attention Deficit and Hyperactivity Disorder (ADHD). Founded in 2012 and based in Kansas City, Kansas, with an additional office in Morristown, New Jersey, the company is advancing two first-line stimulant medications, CTx-1301 and CTx-1302, designed for all patient demographics, including children, adolescents, and adults. These medications aim to address a significant unmet need in the ADHD market by providing full-day therapeutic efficacy through a single daily oral dose. Cingulate has partnered with Catalent Pharma Solutions to leverage their patented OptiDose technology, which enhances drug delivery and manufacturing efficiency. The company holds a robust intellectual property portfolio, including 28 patents, ensuring strong protection throughout the development process. With ongoing research indicating that many patients require additional dosing for optimal results, Cingulate's innovations target the growing $2-$3 billion combination-dose market and the broader $9 billion ADHD market.

Likarda is a biotechnology company focused on developing innovative cell therapies and delivery technologies. Utilizing its patented Core-Shell Spherification® platform, Likarda specializes in cell encapsulation within biocompatible hydrogels, such as Hyaluronic Acid and PEG, which allows for customized delivery solutions tailored to the unique specifications of various cell therapies. The company's approach enables the creation of microcapsules that can provide injectable treatments with enhanced localization and efficacy or offer immunoprotective barriers for long-term cell transplants. Likarda is actively working on therapies for diabetes and osteoarthritis, including the delivery of islet-like cells for diabetes treatment and the slow-release injection of encapsulated stem cells for alleviating joint pain and reversing osteoarthritis degradation. The company has achieved significant recognition, including being named one of the "50 Most Promising Start-Ups in the World." To date, Likarda has secured over $8 million in funding through private investments, grants, and contract services.